Erasca (ERAS) Depreciation & Amortization (CF) (2020 - 2026)
Erasca posted quarterly Depreciation & Amortization (CF) of $723000.0 for Q1 2026, down 12.04% year-on-year from $822000.0 in Q1 2025, and up 3.29% on a QoQ basis from $700000.0 in Q4 2025.
Erasca (ERAS) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $723000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 12.04% year-over-year to $723000.0; the trailing twelve-month figure through Mar 2026 stood at $3.0 million (down 17.55% YoY), and the FY2025 full-year result was $3.1 million, down 18.53% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $723000.0, up from $700000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $1.1 million in Q2 2024 and bottomed at $403000.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $832000.0 (2024), against an average of $819529.4.
- The widest annual swing landed in 2022, when Depreciation & Amortization (CF) surged 303.66%; it then retreated 28.45% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $933000.0 in 2022, then gained by 0.96% to $942000.0 in 2023, then declined by 11.68% to $832000.0 in 2024, then decreased by 15.87% to $700000.0 in 2025, then advanced by 3.29% to $723000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $723000.0 (Q1 2026), $700000.0 (Q4 2025), and $755000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | 723,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 723,000.00 |
| Mar 31, 2026 | 723,000.00 |
| Dec 31, 2025 | 700,000.00 |
| Dec 31, 2025 | 700,000.00 |
| Sep 30, 2025 | 755,000.00 |
| Sep 30, 2025 | 755,000.00 |
| Jun 30, 2025 | 787,000.00 |
| Jun 30, 2025 | 787,000.00 |
| Mar 31, 2025 | 822,000.00 |
| Mar 31, 2025 | 822,000.00 |
| Dec 31, 2024 | 832,000.00 |
| Dec 31, 2024 | 832,000.00 |
| Sep 30, 2024 | 842,000.00 |
| Sep 30, 2024 | 842,000.00 |
| Jun 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 1.10 Mn |
| Mar 31, 2024 | 998,000.00 |
| Mar 31, 2024 | 998,000.00 |
| Dec 31, 2023 | 942,000.00 |
| Dec 31, 2023 | 942,000.00 |
| Sep 30, 2023 | 941,000.00 |
| Sep 30, 2023 | 941,000.00 |
| Jun 30, 2023 | 955,000.00 |
| Jun 30, 2023 | 955,000.00 |
| Mar 31, 2023 | 894,000.00 |
| Mar 31, 2023 | 894,000.00 |
| Dec 31, 2022 | 933,000.00 |
| Dec 31, 2022 | 933,000.00 |
| Sep 30, 2022 | 771,000.00 |
| Sep 30, 2022 | 771,000.00 |
| Jun 30, 2022 | 534,000.00 |
| Jun 30, 2022 | 534,000.00 |
| Mar 31, 2022 | 403,000.00 |
| Mar 31, 2022 | 403,000.00 |
| Dec 31, 2021 | 320,000.00 |
| Dec 31, 2021 | 320,000.00 |
| Sep 30, 2021 | 191,000.00 |
| Sep 30, 2021 | 191,000.00 |
| Jun 30, 2021 | 169,000.00 |
| Jun 30, 2021 | 169,000.00 |
| Mar 31, 2021 | 149,000.00 |
| Mar 31, 2021 | 149,000.00 |
| Dec 31, 2020 | 146,000.00 |
| Dec 31, 2020 | 146,000.00 |
| Sep 30, 2020 | 139,000.00 |
| Sep 30, 2020 | 139,000.00 |
| Jun 30, 2020 | 134,000.00 |
| Jun 30, 2020 | 134,000.00 |